LONDON: Flagship Pioneering, the biotech venture firm that brought the world Moderna Inc, is expanding its footprint with its first full-scale site outside the United States.
The life sciences investment firm will commit £100mil (US$132mil) over the next few years to build out a London-based lab that “will conceive, test, fund and build” artificial intelligence (AI)-focused biotech firms in human health, environmental science and agriculture, the company said in a statement.
Notably, Flagship plans to bring in an additional £500mil in funding for the new lab through yet-to-be announced partnerships.
The venture firm will add 50 scientist- entrepreneurs and company operators to the roughly dozen people it already has in London, with the goal of establishing eight to 10 new UK-based biotechs over the next few years, chief executive officer (CEO) Noubar Afeyan said in an interview.
Some will focus on broad platform technologies, like Moderna does, while others will be centred on single drug assets.
“Our goal is to establish an ecosystem of companies” that can help each other develop while also leveraging the capabilities that Flagship has created in Boston, Afeyan said in the interview.
The billionaire and biochemical engineer said he was attracted to London because of its world-class biomedical research infrastructure, deep AI expertise and strong clinical capabilities.
“The United Kingdom is a natural home for AI and life sciences companies, and we want to see more new businesses across these sectors turning cutting-edge research and technology into new jobs and economic growth,” Chris McDonald, UK minister for science, innovation and investment, said in a statement.
“This new commitment from Flagship Pioneering will kick-start companies of the future in the United Kingdom.”
Flagship takes an unusual approach to the creation of biotechs.
Unlike most venture firms, the company doesn’t spend most of its money developing other peoples’ ideas.
Instead, its roughly 600 employees come up with their own concepts that are often funded by Flagship for years before bringing in outside investors.
Moderna, Flagship’s biggest success story, famously helped pioneer Covid-19 vaccines using mRNA (messenger ribonucleic acid) technology.
In August, Moderna and its partner Merck & Co announced that the companies’ mRNA vaccine for a deadly form of skin cancer had succeeded in a final-stage trial.
That milestone could potentially pave the way for a broad new field of cancer vaccines that could someday help treat numerous tumours.
Moderna’s shares are up more than 600% this year.
The initiative marks a sea change for a firm that’s headquartered nearly every one of its 130-plus companies in the Boston area.
The Cambridge, Massachusetts-based company has been a key part of the Boston area’s elevation into a global life sciences hub over the past quarter-century.
The firm and its related companies occupy more than three million sq ft in Boston, Cambridge and neighboring towns, equal to nearly 9% of the area’s currently used lab space.
That lustre has dimmed slightly, as Massachusetts experienced a decline in biopharmaceutical jobs for the first time in decades last year.
But Afeyan said that Flagship is “doing more, more efficiently, in Boston than we have before”, and that it remains committed to the region.
Furthermore, the CEO didn’t provide a timeline for the additional £500mil in funding for the London lab, but added that “it’s something that we’re working very actively with a number of partners on”. — Bloomberg
